The Home Health Advantage for Patient-Centered Clinical Trials Represented by Firma at SCOPE 2020

|||The Home Health Advantage for Patient-Centered Clinical Trials Represented by Firma at SCOPE 2020

The Home Health Advantage for Patient-Centered Clinical Trials Represented by Firma at SCOPE 2020

Firma Clinical Research, a niche service provider to the drug and medical device industry, will attend SCOPE 2020 to advance the benefits of patient-centered home health in decentralized and virtual clinical trials. SCOPE 2020 will be held February 18-21, 2020, in Orlando for clinical operations executives interested in innovation in clinical trials and digital health.

The Firma team’s engagement at SCOPE 2020 includes:

  • A virtual clinical trial home visit experience in Booth 909: Working with snaploT, Firma will offer summit attendees the opportunity to test the technology used in telehealth and to secure real-time capture. Firma’s home health experts will also offer operational, regulatory and financial perspectives into incorporating home visits into clinical trial sponsor protocols.
  • “Collaborating with Advocacy Organizations to Integrate Patient Perspective into Research” presentation: Firma’s collaboration with The Myositis Association (TMA) to directly improve the patient experience in clinical trials will be presented by Mary McGowan, Executive Director, TMA. The presentation, highlighting the patient-centric collaboration process and the benefits to patients and biotech sponsors, takes place 9:25 a.m. on Friday, February 21.
  • “Mastering an Outsourcing Strategy” session: Firma’s COO, Mike Keens will chair this discussion on Thursday, February 20. The program includes presentations by representatives from Endo Pharmaceuticals, Bayer Healthcare and MyoKardia and will focus on how companies can be a “sponsor of choice” by clinical trial sites. The program will also include a discussion of relationships and site payments.

“The SCOPE 2020 summit provides Firma’s team the opportunity to share our patient-centric approach, which helps improve the efficiencies, participation and overall success of clinical trials,” says Michael J. Woods, CEO, Firma Clinical Research. “Firma offers a home health visit advantage for decentralized or virtual trials, and our collaboration with advocacy partners like The Myositis Association are helping us understand, implement and improve the patient trial experience.”

“The snapIoT mClinical and MHealth technology platforms, being used by the Firm and TMA study, are examples of how partnerships can advance the patient voice in the research process,” says Isaac Etiminan, CEO, snapIoT.

Firma has completed more than 15,000 in-home patient visits globally within the past 3 years. In addition to at-home visit support, Firma offers patient-focused study design, rapid data analysis and quality submissions.

 

About Firma Clinical Research

 Firma is a niche service provider with a patient-centric approach to unlocking positive outcomes in the drug and medical device development process. Using an integrated suite of specialized solutions, Firma makes the clinical trials process easier and more valuable for patients and produces higher-quality data for sites and sponsors. For more information, visit the company at www.firmaclinicalresearch.com or follow Firma Clinical Research on Twitter or LinkedIn.

 

About snapIoT

Based in San Diego, California, with offices in Europe, snapIoT is the fastest-growing “Platform as a Service” provider of de-centralized mClinical & mHealth self-service platform solutions for life-sciences, CROs and Pharma companies with no software coding required. SnapIoT’s senior leadership comes from the chipset division of Qualcomm. They have delivered projects across many patient populations around the globe. Building on this experience, snapIoT has designed and implemented self-service mClinical & mHealth IoT solutions for Life Sciences, CROs and pharmaceutical companies. For more information and to request a free user experience, visit http://www.snapiot.com.

2020-02-04T19:17:18+00:00February 4th, 2020|Categories: News & Media, Press Releases|Tags: , , , , |